1Ospedale Ca' Foncello, Divisione di Cardiologia, Piazza Ospedale 1, 31100 Treviso, Italy
2Department of Cardiology, Niguarda Hospital, Milan, Italy
3Department of Interventional Cardiology, San Camillo Hospital, Rome, Italy
4Astra-Zeneca Spa, Milan, Italy
5Laboratory of Clinical Chemistry, University Hospital, Padua, Italy
6Division of Cardiology, San Martino Hospital, Genoa, Italy
7Department of Interventional Cardiology, Montevergine Hospital, Avellino, Italy
8Division of Cardiology, Civil Hospital, Brescia, Italy
9Division of Cardiology, Santa Croce Hospital, Cuneo, Italy
10Division of Cardiology, Maggiore Hospital, Parma, Italy
Received 4 September 2004; revised 11 January 2005; accepted 20 January 2005; online publish-ahead-of-print 1 March 2005.
* Corresponding author. Tel: +39 0422 322767; fax: +39 0422 322662. E-mail address: clcaval{at}tin.it
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Methods and results The CK-MB and PCI study included 3494 consecutive patients undergoing PCI from February 2000 to October 2000 in 16 Italian tertiary centres. Blood samples were collected at baseline, and at 812 and 1824 h after the procedure, and were analysed in a core biochemistry laboratory. CK-MB elevation was detected in 16% of the patients, and was associated with increased 2-year mortality [7.2 vs. 3.8%; odds ratio (OR): 1.9; 95% confidence interval (CI): 1.32.8; P<0.001). The degree of CK-MB elevation (peak CK-MB ratio) independently predicted the risk of death (adjusted OR per unit: 1.04; 95% CI: 1.011.07; P=0.009). A cTnI elevation was detected in 44.2% of the cases and was not associated with a significant increase in mortality (4.9 vs. 4.0%; OR: 1.2; 95% CI: 0.91.7; P=0.2).
Conclusion Post-procedural elevations of CK-MB, but not cTnI, influence 2-year mortality.
Key Words: Angioplasty Stents Complications Enzymes Prognosis
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The CK-MB and PCI study was a multicentre prospective cohort study of a consecutive series of patients undergoing PCI, which was designed to evaluate the influence of procedural elevations in CK-MB and cTnI on long-term mortality.
![]() |
Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Study protocol
Three blood samples were drawn: the first immediately before the beginning of the percutaneous intervention (baseline), and the second and third at 812 and 1824 h, respectively, after the end of the procedure. Four millilitres of blood was collected in an anticoagulant-free vial and centrifuged at 3000 r.p.m.; after being separated from the red cells, the serum was stored at 70°C and regularly shipped to the core biochemistry laboratory, where CK-MB and cTnI levels were measured. The selection of medications, devices, degree of revascularization, and subsequent hospital care was left to the discretion of the treating physician and was recorded in the case report forms. The patients' vital conditions were assessed after 6, 12, and 24 months by means of clinical examinations, pre-dated questionnaires, or telephone interviews. An independent clinical event committee verified the source data in a randomly selected sample of 10% of the patients and in all of those who died.
Biochemical analyses
Mass CK-MB and cTnI levels were analysed using a Dimension RxL/HM analyser (Dade Behring, Glasgow, DE, USA). The upper reference limit for CK-MB was 5.0 ng/mL; the upper reference limit for cTnI was 0.15 ng/mL, which represented the 99th percentile of the distribution of a reference control group with an analytical imprecision of no more than 10%.15
Definition of CK-MB and cTnI elevation
If the baseline CK-MB level was below the upper reference limit, a CK-MB elevation was defined as a level above the upper reference limit in at least one of the two post-procedural samples. If the baseline level was above the upper reference limit, a CK-MB elevation was defined as an increase of 50% above the baseline level in both post-procedural samples. The same criteria were used to define cTnI elevation. The degree of CK-MB or cTnI elevation was expressed as the CK-MB or cTnI peak ratio, which was calculated by dividing the maximum post-procedural level of the marker by its upper reference limit, or by its baseline value if the baseline value was above the upper reference limit.
Outcome
The outcome of interest was 2 year all-cause mortality, defined as the number of deaths that occurred from the time of the second blood sample up to 24 months thereafter.
Statistical analysis
Continuous variables are expressed as mean (±standard deviation) or median values (with interquartile range); the categorical variables are expressed as proportions. Assuming a 15% incidence of CK-MB elevation and 8% mortality after 2 years in patients without elevation, it was calculated that a sample size of 3850 patients was required to detect a risk ratio of 1.5 with a power of 80% and a two-tailed significance level of 0.05. This sample size was increased to 4000 patients to allow for patients with ST-segment-elevation ACS who were enrolled but prospectively excluded from the analysis. Logistic regression (SAS version 8.0, SAS Institute) was used to calculate the ORs and the corresponding 95% CIs.
A multivariable logistic regression analysis was performed to ascertain whether CK-MB levels independently predicted the risk of death and included the variables known to influence mortality in this population. These were age, diabetes, previous coronary artery bypass graft surgery, chronic renal insufficiency (serum creatinine >2.0 md/dL), peripheral arterial disease, the presence of non-ST-segment elevation ACS, the presence of multivessel disease, left ventricular ejection fraction, an unsuccessful procedure [a residual coronary lumen narrowing of >50% or a Thrombolysis in Myocardial Infarction (TIMI) grade flow of <3 in one attempted coronary lesion], and the CK-MB peak ratio. The quartiles of the distribution of age, ejection fraction, and CK-MB were determined. Two analyses were performed considering the quartiles as qualitative and quantitative variables. The difference in deviance between these two models was then used to decide whether the effects were linear.
Additional analyses excluding patients with high baseline CK-MB levels or procedural complications were also made, in order to investigate further the role of high cardiac markers before PCI and the potential co-linearity between CK-MB elevations and procedural complications (side branch closure, transient abrupt vessel closure, distal thromboembolism, and transient slow flow). A two-sided P-value of 0.05 was considered statistically significant.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
CK-MB elevation and mortality
CK-MB elevation was detected in 559 patients (16.0%): 496 with a normal baseline level and 63 with a baseline level above the upper reference limit. The distributions of the clinical, angiographic, and procedural variables in patients with and without CK-MB elevation are shown in Table 1.
|
|
|
Two year mortality was not significantly higher in patients with cTnI elevations (75/1544 or 4.9%) than in those without (78/1950 or 4.0%; OR: 1.2; 95% CI: 0.91.7; P=0.2). The relationship between the cTnI peak ratio and the adjusted probability of death is shown in Figure 2.
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Severe acute complications are rare, but a mild and asymptomatic release of the biochemical markers of myocardial necrosis is frequently observed after otherwise technically successful interventions.16 A recent magnetic resonance imaging study has shown that such increases in the CK-MB isoenzyme are due to detectable myocardial necrosis,17 and the Joint Ad Hoc Committee of the European Society of Cardiology and American College of Cardiology for the Redefinition of Myocardial Infarction has taken an unequivocal position by defining any elevation in the markers of myocardial damage in the setting of coronary interventions as myocardial infarction.18 A few retrospective studies have suggested an association between CK-MB elevations after PCI and increased long-term mortality,26 whereas others have highlighted a higher risk only for major enzyme release (more than five to eight times the upper reference limit).710 The potential methodological limitations of the published reports, such as study design (retrospective or post hoc evaluations vs. prospective studies), patient selection (selected subsets vs. the general population), long enrolment times (up to 6 or 8 years in single-centre series), lack of statistical power, and inadequate duration of follow-up may partially account for these inconsistent conclusions.
The major findings of our prospective cohort study are that procedural elevations in CK-MB affect 2 year mortality and that there is a linear relationship between the degree of elevation and the risk of death, regardless of other variables. Finally, an increase in cTnI does not affect 2 year mortality and therefore does not add any further prognostic information to that offered by CK-MB levels.
It is only possible to speculate as to why procedural CK-MB elevations influence long-term mortality. One potential mechanism may be related to the myocardial damage per se, which leads to increased mortality as a result of reduced ventricular function or electrical instability. Alternatively, high CK-MB levels may be a sign of a more active atherosclerotic process and hence be associated with an adverse prognosis due to a more frequent recurrence of ischaemic events. However, regardless of the mechanism involved, it is interesting to note that antithrombotic drugs such as platelet glycoprotein IIb/IIIa receptor inhibitors, which have consistently been shown to reduce post-procedural myocardial damage, also reduce long-term mortality especially in the high-risk subset of patients.19,20 This observation indirectly supports the concept of an effect of CK-MB elevation on mortality.
The fact that slight increases in cTnI do not predict an increased risk of death may be due to the high sensitivity of this marker in detecting myocardial cell damage, as expressed by the high rate of cTnI elevations in this study. It is, therefore, possible to hypothesize that even the mild and potentially reversible myocardial injuries21 caused by transient procedure-induced ischaemia lead to troponin elevations, and that these do not influence the prognosis. Alternatively, the sensitivity of the test may reduce its ability to predict prognosis: the increased risk associated with troponin elevations could be so small that only studying a larger number of patients for a longer follow-up time would reveal any significant effect on survival.
Study limitations
First of all, as in other previous studies, no independent angiographic core laboratory analyses were performed, and the description of variables that are potentially relevant for prognosis, such as lesion morphology, the extension of coronary artery disease, the result of the procedure, and the degree of revascularization, were left to the operator's evaluation. Secondly, serum samples were collected only in the first 24 h after the procedure, with the potential risk of underestimating the degree of marker elevation in cases of a delayed peak associated with large myocardial necrosis. Finally, post-procedural ECG was not considered in the analysis: Q-wave myocardial infarctions were not adjudicated nor was the prognostic impact of Q-wave vs. non-Q-wave myocardial infarction examined. However, the aim of the study was to assess the clinical relevance of minor marker elevations, which are usually characterized by a rapid return to normal values and not normally associated with significant ECG changes.
Another possible limitation of this study may be the infrequent use of GPIIb/IIIa antagonists (20%). These were more frequently used in the group of patients with CK-MB elevation; a difference that probably reflects their more frequent use in patients with high-risk clinical and angiographic characteristics, such as acute coronary syndrome or a complex anatomy, or in bail-out situations after procedural complications have developed.
In conclusion, our results demonstrate that CK-MB elevations in patients undergoing PCI affect 2 year mortality and that the risk of death increases linearly with any elevation of the marker. Procedural CK-MB elevations should, therefore, be prevented,19,20,22 systematically sought, and, if detected, always be reported in order to define the patient's risk profile more precisely. Further evaluations are necessary to establish whether aggressive secondary prevention strategies23,24 can improve the long-term outcome of patients with procedure-induced myocardial necrosis.
![]() |
Acknowledgements |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
Appendix |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Statistical analysis
Gustavo Arraiz (Milan).
Biochemistry core laboratory
Mario Plebani, Martina Zaninotto (Institute of Clinical Chemistry, University of Padua).
Study monitors
Renata Colli (Milan), Alessandro Daniotti (Montebelluna).
Investigators at the participating hospitals
Z. Olivari, R. Zecchel, Ca' Foncello Hospital, Treviso; P. Rubartelli, C. Giachero, San Martino Hospital, Genoa; S. Klugmann, M. Rossi, Niguarda Ca' Granda Hospital, Milan; S. Battaglia, A. Cioppa, Montevergine Hospital, Mercogliano; O. Lenzi, F. Ettori, Civil Hospital, Brescia; G. Steffenino, M. Dutto, Santa Croce Hospital, Cuneo; F. Castriota, R. Manetti, Villa Maria Cecilia Hospital, Cotignola; L. Angoli, U. Canosi, San Matteo Hospital, Pavia; G. Bernardi, L. Spedicato, Santa Maria della Misericordia Hospital, Udine; M. Sansa, A.S. Bongo, Maggiore Hospital, Novara; R. Violini, E. Pucci, San Camillo Hospital Rome, E. Aurier, C. Piscicelli, Maggiore Hospital, Parma; S. De Servi, R. Fetiveau, Civil Hospital, Legnano; W. Pitcheider, E. Apuzzo, Civil Hospital, Bolzano; G. Danzi, C. Capuano, Poliambulanza Hospital, Brescia; B. Reimers, S. Span, Civil Hospital, Mirano.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|